Joseph Swedish and Vas Narasimhan are prominent American healthcare executives, but there is no verified public evidence of a direct personal, family, employment, or shared-board relationship between them. Their clearest connection is through the healthcare industry itself: Swedish built much of his career in hospital systems and health insurance, while Narasimhan leads Novartis from the pharmaceutical research and medicines side.
The pairing “joseph swedish and vas narasimhan” therefore makes most sense as a comparison of two influential healthcare leaders who have approached similar industry problems from different parts of the system. Both have dealt with healthcare access, affordability, technology, data, innovation and relationships among patients, providers, insurers and drug companies, but their careers have followed distinctly different paths.
Joseph Swedish and Vas Narasimhan at a Glance
| Detail | Joseph Swedish | Vas Narasimhan |
|---|---|---|
| Primary field | Healthcare delivery and health insurance | Pharmaceuticals and drug development |
| Best-known executive role | Former CEO and chairman of Anthem, now Elevance Health | CEO of Novartis |
| Major organization | Anthem | Novartis |
| CEO period | Anthem CEO, 2013 to November 2017 | Novartis CEO since February 1, 2018 |
| Earlier experience | Trinity Health, Centura Health, HCA | Novartis drug development and vaccines |
| Major trade-group leadership | Former chairman of AHIP | PhRMA chair, 2023–2024 |
| Current notable roles | CDW director, Navitus board member, Concord Health Partners partner emeritus | Novartis CEO, Anthropic director, PhRMA board member |
| Core perspective | Payers, providers and healthcare delivery | Medicines, science, R&D and global pharmaceuticals |
Swedish’s current and past positions are documented in CDW’s 2026 proxy statement, Navitus Health Solutions and Concord Health Partners. Narasimhan’s current roles and career history are documented by Novartis.
Is There a Direct Connection Between Joseph Swedish and Vas Narasimhan?
There is no clearly documented direct business partnership between Joseph Swedish and Vas Narasimhan in the authoritative corporate records and public biographies reviewed for this article. There is also no verified evidence that one worked for the other, that they have served together on the same corporate board, or that they are related.
Their senior leadership timelines did briefly intersect in 2018. Swedish had stepped down as Anthem CEO in November 2017 but remained executive chairman until his retirement in May 2018. Narasimhan officially became CEO of Novartis on February 1, 2018. This means both occupied senior leadership positions at major healthcare companies for several months in early 2018, although at different organizations and in different parts of the healthcare sector.
That timing should not be mistaken for evidence of collaboration. No reliable source reviewed establishes a specific joint project between them.
Who Is Joseph Swedish?
Joseph R. Swedish is an American healthcare executive best known for leading Anthem Inc., now Elevance Health, one of the largest health-benefits companies in the United States.
According to CDW’s April 2026 proxy filing with the U.S. Securities and Exchange Commission, Swedish served as Anthem’s president and CEO from 2013 until November 2017. He became chairman in 2015 and executive chairman in November 2017, retiring from that position in May 2018. He subsequently remained a senior adviser to Anthem until May 2020.
His Career Before Anthem
Swedish’s healthcare experience extends well beyond insurance. Before Anthem, he led major healthcare-delivery organizations.
He served as president and CEO of Trinity Health from 2004 to 2013. Earlier in his career, he held senior executive and CEO positions at organizations including Centura Health and Hospital Corporation of America.
That background gave Swedish experience on both the healthcare-provider and health-insurance sides of the industry. This distinction becomes important when comparing him with Narasimhan, whose career developed mainly around pharmaceutical science, vaccines and drug development.
Swedish’s Approach to Healthcare
During Swedish’s Anthem leadership, technology, healthcare costs and value-based care were recurring themes.
At the 2017 AHIP Institute, Swedish discussed problems involving healthcare affordability, access and quality and argued for changes in the way healthcare organizations collaborate and deliver care. He also described Anthem’s use of large healthcare datasets as the industry moved toward value-based reimbursement.
His career therefore represents the financing and delivery side of healthcare, where insurers and providers must determine how care is funded, coordinated and made available to large populations.
What Is Joseph Swedish Doing Now?
Swedish remains involved in corporate governance and healthcare investment rather than running a large insurance company.
CDW’s 2026 proxy statement identifies him as an independent director who has served on its board since 2015. The filing listed him as 74 at the time of the proxy and described him as a co-founder and partner emeritus of healthcare-focused investment firm Concord Health Partners.
Concord’s current team page also lists Joseph Swedish as Partner Emeritus.
Navitus Health Solutions, a pharmacy benefit management company, lists Swedish as a member of its board. Its biography describes his experience at Anthem and his broader work involving healthcare costs, physicians, access and the consumer experience.
Swedish is also listed among the trustees of Trout Unlimited, showing that some of his current board activity extends beyond healthcare.
Also Read: Ian McKellen and Vas Narasimhan
Who Is Vas Narasimhan?
Vasant “Vas” Narasimhan, M.D., is an American physician and healthcare executive who has served as chief executive officer of Novartis since 2018.
Unlike Swedish, whose career moved through hospitals and insurance, Narasimhan’s professional development has centered on medicine, vaccines, drug research and pharmaceutical management.
Novartis states that he joined the company in 2005 and later held positions including:
- North America Region Head for Novartis Vaccines
- U.S. Country President for Novartis Vaccines and Diagnostics
- Global Head of Development for Novartis Vaccines
- Global Head of Development for Novartis Pharmaceuticals
- Global Head of Drug Development and Chief Medical Officer
He became Novartis CEO on February 1, 2018, succeeding Joseph Jimenez.
Narasimhan’s Medical and Public-Policy Background
Narasimhan holds a medical degree from Harvard Medical School, a master’s degree in public policy from Harvard University’s John F. Kennedy School of Government and a bachelor’s degree in biological sciences from the University of Chicago.
Before and during his medical training, he worked on global public-health issues involving diseases such as HIV/AIDS, tuberculosis and malaria. Novartis says he has overseen the approval of more than 35 novel medicines and vaccines during his career.
His combination of medicine, public policy and corporate management differs substantially from Swedish’s health-system and insurance background.
What Is Vas Narasimhan Doing in 2026?
As of September 2026, Narasimhan remains CEO of Novartis. The company’s current executive committee is led by him, and Novartis describes itself under his leadership as a focused innovative-medicines business.
Novartis says its medicines reached more than 300 million patients in 2025, while the company employed more than 77,000 people and operated in approximately 120 countries.
Narasimhan has also expanded his activities outside Novartis.
In April 2026, Anthropic’s Long-Term Benefit Trust appointed him to Anthropic’s board of directors. Anthropic highlighted his experience bringing medicines through heavily regulated development and approval processes and the potential application of artificial intelligence in healthcare and life sciences.
He also remains on the board of the Pharmaceutical Research and Manufacturers of America, or PhRMA.
Where the Careers of Joseph Swedish and Vas Narasimhan Intersect
Although there is no confirmed direct partnership, their careers intersect around several major healthcare issues.
1. Healthcare Access
Both executives have worked on questions involving access to healthcare, but from different positions.
For Swedish, access generally relates to insurance coverage, healthcare networks, healthcare delivery and the affordability of medical services.
For Narasimhan, access involves whether new medicines can reach patients after discovery, clinical development and regulatory approval. Novartis explicitly identifies access to innovative medicines, including in lower-income countries, as an area Narasimhan has championed.
The distinction is important. Access to a physician or hospital and access to a newly developed medicine are connected problems, but the organizations solving them operate under different economic and regulatory structures.
2. Healthcare Costs and Affordability
Swedish’s experience at Anthem placed him on the payer side of healthcare spending. Insurers evaluate medical utilization, provider reimbursement, prescription costs and population-level healthcare expenditures.
Narasimhan represents the pharmaceutical-manufacturer side, where companies invest in research and clinical development and then negotiate access to medicines within different national healthcare and reimbursement systems.
These two sides frequently interact across the healthcare system even when individual executives do not work together.
3. Data and Technology
Technology is another important common theme.
Swedish spoke publicly during his Anthem tenure about using large volumes of health information to improve efficiency and support value-based healthcare. Anthem was processing hundreds of millions of claims, giving the company substantial data for analyzing healthcare use and outcomes.
Narasimhan has emphasized data science, digital technologies and artificial intelligence as tools for improving drug discovery and development. Novartis describes technology leadership and data science as major elements of the company’s transformation under him.
His appointment to Anthropic’s board in 2026 further connects his work with the growing use and governance of AI in healthcare and scientific research.
Their Trade-Association Leadership Shows an Important Difference
One of the most useful ways to understand Joseph Swedish and Vas Narasimhan is through the healthcare trade organizations they have led.
Swedish served as chairman of America’s Health Insurance Plans, or AHIP, during his Anthem era. In 2017, he opened AHIP’s major industry conference while serving as the association’s board chairman.
Narasimhan later became chairman of PhRMA, the major U.S. trade organization representing research-based pharmaceutical manufacturers. He assumed the chair in February 2023 and served during the 2023–2024 period.
The distinction neatly illustrates their positions within healthcare:
AHIP represents health insurers. PhRMA represents pharmaceutical manufacturers.
Swedish therefore became a prominent voice from the insurance side, while Narasimhan became a prominent voice from the innovative-medicines side.
This does not establish a personal relationship between them, but it explains why their careers belong to the same broader discussion about how the U.S. healthcare system funds, develops and delivers treatment.
Leadership Styles Shaped by Different Backgrounds
Swedish entered senior healthcare management through hospital administration. His education includes a master’s degree in health administration from Duke University, and much of his career involved running healthcare systems before he became CEO of a major insurer.
Narasimhan entered pharmaceutical leadership with training as a physician and public-policy specialist. His career inside Novartis moved through vaccines and drug development before reaching the CEO position.
The result is two different executive perspectives.
Swedish’s experience is particularly associated with how healthcare is organized, financed and delivered.
Narasimhan’s is associated with how medicines are discovered, developed, approved and brought to patients.
Both ultimately address patient outcomes, but from different points in the healthcare value chain.
Did Swedish Work for Novartis?
No reliable corporate record reviewed indicates that Joseph Swedish has worked for Novartis.
His principal executive career includes HCA-related roles, Centura Health, Trinity Health and Anthem, followed by board and investment positions. CDW’s detailed 2026 biography does not list Novartis among his employers.
Did Narasimhan Work for Anthem or Elevance Health?
No. Narasimhan joined Novartis in 2005 and has spent most of his corporate career there, apart from earlier work that included McKinsey & Company and public-health activities.
There is no verified record showing him as an executive or employee of Anthem or its renamed successor, Elevance Health.
Are Joseph Swedish and Vas Narasimhan Related?
There is no credible evidence that Joseph Swedish and Vas Narasimhan are relatives.
Their appearance together in a search query should not be interpreted as evidence of a family relationship. Available authoritative biographies describe separate backgrounds, careers and professional networks.
FAQ
What is the connection between Joseph Swedish and Vas Narasimhan?
Their verified connection is primarily through the broader healthcare industry. Swedish is a former Anthem CEO with extensive hospital and insurance experience, while Narasimhan is the current CEO of Novartis and has a pharmaceutical and medical-development background. No reliable public evidence establishes a direct personal or corporate partnership between them.
Did Joseph Swedish and Vas Narasimhan work together?
No confirmed public record reviewed shows Swedish and Narasimhan working together at the same company or on the same board. They did occupy senior positions in the healthcare industry at the same time.
Who is Joseph Swedish?
Joseph Swedish is the former chairman, president and CEO of Anthem, now Elevance Health. He previously led Trinity Health and other healthcare systems and currently holds board and investment-related positions including a CDW directorship.
Who is Vas Narasimhan?
Vas Narasimhan is a physician and the CEO of Novartis, a position he has held since February 2018. He previously led major Novartis drug-development and vaccine operations and became an Anthropic board member in 2026.
Are Joseph Swedish and Vas Narasimhan in the same industry?
Broadly, yes. Both are healthcare executives, but they operate in different segments. Swedish’s career centers on hospitals, healthcare delivery and insurance, while Narasimhan’s centers on pharmaceutical research, drug development and medicines.
Are Joseph Swedish and Vas Narasimhan related?
No verified information indicates a family relationship between them. Their names are connected by their prominence in healthcare rather than by a documented personal relationship.
Also Read: Larry Page and Vas Narasimhan
